Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI258 hepatic impairment pharmacokinetics study in adult cancer patients
NL-OMON39786Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dovitinib in Nonhematologic neoplasms and hepatocellular carcinoma (HCC) (4 arms), sponsored by Novartis. Primary endpoint: Pharmacokinetic parameters after single dose and at steady state. Started Feb 2012; status: active, not recruiting.
02
Drugs
dovitinib
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON39786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39786.